Partner with Us

Triphase is actively in-licensing compounds from biotechnology and pharmaceutical companies as well as academia, in pursuit of promising new drugs with potential in oncology indications.

What are we looking for

Early-phase candidates that may have been deprioritized by large pharmaceuticals companies and, or their progress stagnated due to lack of compelling clinical data. Promising compounds that have substantial but unrecognized medical and commercial value. Products with scientific merit, addressing an unmet medical need, and the ability to rapidly achieve proof of concept in a select patient population. Candidates that have moved out of the discovery stage and are ready to advance in the pre-IND or IND-enabling phase.

Why Triphase

We have a proven track record of accelerating drug candidates from early development through to a profitable exit event. We have a strategic relationship with Bristol-Myers Squibb, one of the top cancer biopharmaceutical companies in the world. Founded by OICR and Toronto Innovation Acceleration Partners (TIAP, formerly MaRS Innovation), we have a strategic relationship with both institutions, enabling access to biomarkers, tumor bank, genomics technology, as well as Toronto’s top universities and research institutes. We have both experience and access to global clinical trial footprint, including the U.S., Canada, Europe, and Australia, which provides many strategic, operational, and financial advantages. Our resources are focused on science-based product development, not “fixed costs”

get in touch